OCUL

Ocular Therapeutix Inc

OCUL, USA

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

https://www.ocutx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OCUL
stock
OCUL

H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission Yahoo Finance UK

Read more →
OCUL
stock
OCUL

Fed Meeting: How analysts rate OCUL stock today - Trade Volume Report & Verified Chart Pattern Signals moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$22.9167

Analyst Picks

Strong Buy

6

Buy

6

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

10.41

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-26.88 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-16.89 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-389.98 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.59

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 95.56% of the total shares of Ocular Therapeutix Inc

1.

FMR Inc

(11.2694%)

since

2025/06/30

2.

Deep Track Capital, LP

(8.2154%)

since

2025/06/30

3.

SUMMER ROAD LLC

(7.9815%)

since

2025/06/30

4.

VR Adviser, LLC

(7.3349%)

since

2025/06/30

5.

BlackRock Inc

(6.0613%)

since

2025/06/30

6.

Fidelity Growth Compy Commingled Pl S

(4.9937%)

since

2025/07/31

7.

Vanguard Group Inc

(4.8232%)

since

2025/06/30

8.

venBio Select Advisor LLC

(4.253%)

since

2025/06/30

9.

Fidelity Growth Company Fund

(3.8588%)

since

2025/07/31

10.

TCG Crossover Management, LLC

(3.0571%)

since

2025/06/30

11.

Citadel Advisors Llc

(2.8081%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(2.7027%)

since

2025/07/31

13.

Adage Capital Partners Gp LLC

(2.2358%)

since

2025/06/30

14.

State Street Corp

(2.0168%)

since

2025/06/30

15.

Paradigm Biocapital Advisors LP

(1.9658%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(1.95%)

since

2025/08/31

17.

Geode Capital Management, LLC

(1.8875%)

since

2025/06/30

18.

Deltec Asset Management LLC

(1.6063%)

since

2025/06/30

19.

Morgan Stanley - Brokerage Accounts

(1.478%)

since

2025/06/30

20.

Octagon Capital Advisors LP

(1.3937%)

since

2025/06/30

21.

Logos Global Management LP

(1.2644%)

since

2025/06/30

22.

UBS Group AG

(1.1294%)

since

2025/06/30

23.

Point72 Asset Management, L.P.

(1.0944%)

since

2025/06/30

24.

Fidelity Growth Company K6

(1.0464%)

since

2025/07/31

25.

Susquehanna International Group, LLP

(1.028%)

since

2025/06/30

26.

Fidelity Series Growth Company

(1.0229%)

since

2025/07/31

27.

Fidelity Small Cap Index

(0.8117%)

since

2025/06/30

28.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7945%)

since

2025/07/31

29.

Fidelity Select Pharmaceuticals Port

(0.7508%)

since

2025/07/31

30.

iShares Russell 2000 Growth ETF

(0.711%)

since

2025/08/31

31.

Strategic Advisers Fidelity US TtlStk

(0.5927%)

since

2025/07/31

32.

Invesco Pharmaceuticals ETF

(0.5134%)

since

2025/08/29

33.

Fidelity Select Biotechnology

(0.4275%)

since

2025/07/31

34.

Artisan International Small-Mid Investor

(0.4136%)

since

2025/06/30

35.

Artisan Non-U.S. Small-Mid Growth Comp

(0.4136%)

since

2025/06/30

36.

Fidelity Extended Market Index

(0.4022%)

since

2025/07/31

37.

Vanguard Russell 2000 ETF

(0.3811%)

since

2025/07/31

38.

Schwab US Small-Cap ETFâ„¢

(0.3522%)

since

2025/08/30

39.

State St Russell Sm Cap® Indx SL Cl I

(0.2731%)

since

2025/08/31

40.

UTM IM GBP AXA Framlington Biotech

(0.2418%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.38

EPS Estimate

-0.3825

EPS Difference

0.0025

Surprise Percent

0.6536%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.